CELLULAR AND HUMORAL IMMUNOGENICITY OF DIFFERENT FORMULATIONS BASED ON RECOMINANT TRANSIALIDASES FOR THE DEVELOPMENT OF A MUCOSAL VACCINE AGAINST T. cruzi

PACINI MF1, GONZÁLEZ FB1, BULFONI, VILLAR S1,2, ESPARIZ M3, BLANCATO V3, MAGNI C3, BOTTASSO O1, PÉREZ AR1 BALBI C1, FARRÉ C 1,2, DINATALE B1; PROCHETTO E4, BONTEMPI I4, CABRERA G4, MARCIPAR

Tucuman

Congreso; LXVII Reunión Anual de la Sociedad Argentina de Inmunología; 2019

SAI

Currently, there are no prophylactic vaccines to fight Chagas disease. Some antigens derivedfrom parasite Transialidase (TS) family have shown promising results as vaccine candidates inmouse models. Here, we evaluated the immunogenicity of different fragments of recombinantTS (TSNt and TSCt), pooled or not. TS fragments were selected by bioinformatics, coveringdifferent regions containing B and T epitopes, some of them immunodominant. Vaccineformulations comprised such recombinant TS with adjuvants (c-di-AMP or ISPA). Theseformulations were used to immunize BALB/c mice (n=5-6/group) intranasally (three doses, oneevery two weeks). As controls, groups of mice were treated with PBS (non-immunized) or withTS fragments, c-di-AMP or ISPA alone. Fifteen days after the last immunization, cell-mediatedimmunity was evaluated in vivo (delayed hypersensitivity test-DHT) and in vitro (flowcytometry). Specific humoral immunity was also measured (ELISA). Results indicated thatimmunized groups TSNt+ISPA, TSCt+ISPA, TSNt+c-di-AMP, TSCt+c-di-AMP, TS(Nt+Ct)+ISPA andTS(Nt+Ct)+c-di-AMP generated an increased cellular response by DHT after 24 and 48 hourscompared with control groups (p